Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
GammaDelta Therapeutics Ltd
GammaDelta Therapeutics Ltd
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
N4 Pharma and SRI to target and treat previously unreachable human cells
The companies will collaborate to perform research to conjugate SRI’s MGS system to Nuvec to increase intracellular delivery to specific target cells.
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Takeda Pharmaceutical to acquire GammaDelta Therapeutics
Abingworth was the founding investor in GammaDelta and provided initial seed funding as part of the company’s creation in 2016
Regulatory
FDA grants IND clearance to GammaDelta cancer therapy
The FDA also granted orphan drug designation to allogeneic Vδ1 γδ T cell therapy (GDX012) for the treatment of Acute Myeloid Leukaemia (AML)
Research & Development
GammaDelta announces publication of new data in Nature Immunology
Findings support the development of gamma delta T cells for gastrointestinal diseases
Pharmaceutical
GammaDelta Therapeutics appoints CMO
Research & Development
Collaboration to advance tissue-derived gamma delta T Cells
Global R&D company Takeda collaborates with GammaDelta, developers of immunotherapies for cancer and other serious diseases
Research & Development
GammaDelta Therapeutics expands management team
Paolo Paoletti leads as Chief Executive Officer
Subscribe now